IB 

Union Calendar No. 449 

116TH CONGRESS 

2D SESSION H. R. 4764 

[Report No. 116–549] 

To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and 

for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

OCTOBER 18, 2019 

Ms. MATSUI (for herself, Mr. BILIRAKIS, and Ms. PINGREE) introduced the 

following bill; which was referred to the Committee on Energy and Commerce 

SEPTEMBER 29, 2020 

Additional sponsors: Mr. FITZPATRICK, Ms. JACKSON LEE, Mr. BUDD, Mr. 

ADERHOLT, Mr. WALDEN, Mr. SWALWELL of California, Mr. HASTINGS, 

Mr. NEGUSE, Mr. YOUNG, Mr. WELCH, Mr. BROWN of Maryland, Mr. 

ROUDA, Mr. BUTTERFIELD, Mr. CRIST, Mr. LOWENTHAL, Mr. SCHRADER, Mr. HARDER of California, Mr. RUSH, Mr. CASTEN of Illinois, Ms. 

DEGETTE, Mrs. AXNE, Mr. CARTWRIGHT, Mr. GRIJALVA, Mr. MCGOVERN, Ms. SEWELL of Alabama, Mr. HUDSON, Mr. WALTZ, Mr. AGUILAR, 

Mrs. BEATTY, Mr. PANETTA, Mr. TIFFANY, Mrs. RODGERS of Washington, Mr. STANTON, Ms. OMAR, Mr. HECK, Mr. TRONE, Ms. CRAIG, 

Mr. SUOZZI, Ms. MCCOLLUM, Ms. DEAN, Mrs. NAPOLITANO, Mr. CASE, 

Mr. GOTTHEIMER, Mr. EMMER, Mr. JOHNSON of Georgia, Ms. 

BROWNLEY of California, Mrs. WAGNER, Mrs. HAYES, Mr. SMITH of 

Washington, and Mrs. MURPHY of Florida 

SEPTEMBER 29, 2020 

Reported from the Committee on Energy and Commerce; committed to the 

Committee of the Whole House on the State of the Union and ordered 

to be printed 


kjohnson on DSK79L0C42PROD with BILLS
2 

•HR 4764 RH

A BILL 

To reauthorize the Stem Cell Therapeutic and Research Act 

of 2005, and for other purposes. 


kjohnson on DSK79L0C42PROD with BILLS
3 

•HR 4764 RH

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Timely ReAuthoriza5 tion of Necessary Stem-cell Programs Lends Access to 

6 Needed Therapies Act of 2019’’ or the ‘‘TRANSPLANT 

7 Act of 2019’’. 

8 SEC. 2. REAUTHORIZATION OF THE C.W. BILL YOUNG CELL 

9 TRANSPLANTATION PROGRAM. 

10 (a) ADVISORY COUNCIL MEETINGS.—Subsection (a) 

11 of section 379 of the Public Health Service Act (42 U.S.C. 

12 274k) is amended by adding at the end the following new 

13 paragraph: 

14 ‘‘(7) The Secretary shall convene the Advisory 

15 Council at least two times each calendar year.’’. 

16 (b) INCREASING COLLECTION.— 

17 (1) TECHNICAL CLARIFICATION.—Effective as 

18 if included in the enactment of Public Law 114–104 

19 (the Stem Cell Therapeutic and Research Reauthor20 ization Act of 2015), the amendment to section 

21 379(d)(2)(B) of the Public Health Service Act (42 

22 U.S.C. 274k(d)(2)(B)) in section 2(a)(2) of Public 

23 Law 114–104 is amended by inserting ‘‘goal of in24 creasing collections of high quality’’ before ‘‘cord 

25 blood units,’’. 


kjohnson on DSK79L0C42PROD with BILLS
4 

•HR 4764 RH

1 (2) ELIMINATING DEADWOOD.—Subparagraph 

2 (B) of section 379(d)(2) of the Public Health Serv3 ice Act (42 U.S.C. 274k(d)(2)) is amended by strik4 ing the second and third sentences in such subpara5 graph. 

6 (c) PERIODIC REVIEW OF STATE OF SCIENCE.—Sec7 tion 379 of the Public Health Service Act (42 U.S.C. 

8 274k) is amended by adding at the end the following new 

9 subsection: 

10 ‘‘(o) PERIODIC REVIEW OF STATE OF SCIENCE.— 

11 ‘‘(1) REVIEW.—Not less than every two years, 

12 the Secretary, in consultation with the Director of 

13 the National Institutes of Health, the Commissioner 

14 of Food and Drugs, the Administrator of the Health 

15 Resources and Services Administration, the Advisory 

16 Council, and other stakeholders, where appropriate 

17 given relevant expertise, shall conduct a review of 

18 the state of the science of using adult stem cells and 

19 birthing tissues to develop new types of therapies for 

20 patients, for the purpose of considering the potential 

21 inclusion of such new types of therapies in the Pro22 gram. 

23 ‘‘(2) RECOMMENDATIONS.—Not later than 

24 June 30, 2024, the Secretary shall— 


kjohnson on DSK79L0C42PROD with BILLS
5 

•HR 4764 RH

1 ‘‘(A) complete the second review required 

2 by paragraph (1); and 

3 ‘‘(B) informed by such review, submit to 

4 the Committee on Health, Education, Labor, 

5 and Pensions of the Senate and the Committee 

6 on Energy and Commerce of the House of Rep7 resentatives recommendations on the appro8 priateness of the inclusion of new types of 

9 therapies in the Program.’’. 

10 (d) AUTHORIZATION OF APPROPRIATIONS.—Section 

11 379B of the Public Health Service Act (42 U.S.C. 274m) 

12 is amended by striking ‘‘$33,000,000 for fiscal year 2015 

13 and $30,000,000 for each of fiscal years 2016 through 

14 2020’’ and inserting ‘‘$30,000,000 for each of fiscal years 

15 2021 through 2025’’. 

16 SEC. 3. CORD BLOOD INVENTORY. 

17 Subsection (g) of section 2 of the Stem Cell Thera18 peutic and Research Act of 2005 (42 U.S.C. 274k note) 

19 is amended to read as follows: 

20 ‘‘(g) AUTHORIZATION OF APPROPRIATIONS.—To 

21 carry out this section, there is authorized to be appro22 priated $23,000,000 for each of fiscal years 2021 through 

23 2025.’’. 


kjohnson on DSK79L0C42PROD with BILLS
Union Calendar No. 449 

116TH CONGRESS 

2D SESSION H. R. 4764 

[Report No. 116–549] 

A BILL 

Research Act of 2005, and for other purposes. 

To reauthorize the Stem Cell Therapeutic and 

SEPTEMBER 29, 2020 

Reported from the Committee on Energy and Commerce; 

the State of the Union and ordered to be printed committed to the Committee of the Whole House on 


kjohnson on DSK79L0C42PROD with BILLS